Proteomics Core Facility
The mission of the Proteomics Core Facility is to provide cost-effective, state-of the-art instrumentation and analytical proteomics expertise to investigators. The Proteomics Core provides a full array of services, including study design, sample preparation, data generation and analysis and interpretation of results. The Proteomics Core supports investigators engaged in basic, preclinical and clinical cancer research, including scientists examining basic mechanisms in of disease, as well as those seeking to identify novel targets for therapy or biomarkers that can be used for early detection, diagnosis, prognosis or response to therapy. The core also provides specialized services, including top-down proteomics and epiproteomics, a reflection of its distinct strengths and pioneering work in technology development.
Services & Equipment
- Protein identification from gels, IP and BioID samples
- Quantitative proteomics, labeled and label-free
- Top-down proteomics, qualitative and quantitative
- Site-specific PTM analyses, including phosphorylation, acetylation, methylation, glycosylation, palmitoylation and ubiquitination
- Targeted proteomics using SRM/MRM/PRM
- Histone Modification Panel analysis, covering all major histone marks
- Advanced proteomics sample preparation from body fluids (blood, urine, saliva, CSF), tissue, secretome, exosome and mitochondria
- Thermo Q-Exactive HF
- Thermo Orbitrap Velos
- Thermo TSQ Quantiva
- Thermo TSQ Quantum Ultra
- Thermo UltiMate™ 3000 RSLCnano System (x4)
Investigating mitochondrial respiration and haematopoietic stem cell function. In collaboration with Dr. Chandel, the Proteomics Core helped show the mitochondrial respiratory chain is dispensable for adult or fetal HSC proliferation, but essential for fetal HSC differentiation and maintenance of adult HSC quiescence.
Epiproteomic profiling of diffuse intrinsic pontine glioma cells. In collaboration with Dr. Shilatifard, the Proteomics Core helped show Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.
Spherical nucleic acids for cancer therapeutics. In collaboration with Dr. Mirkin, the core contributed to this study by demonstrating that G-rich Spherical nucleic acids (SNAs) adsorb more types of proteins and more total protein from serum than do poly-T SNAs.
Work performed in the proteomics core should be acknowledged as shown below:
Proteomics services were performed by the Northwestern Proteomics Core Facility, generously supported by NCI CCSG P30 CA060553 awarded to the Robert H. Lurie Comprehensive Cancer Center, instrumentation award (S10OD025194) from NIH Office of Director, and the National Resource for Translational and Developmental Proteomics supported by P41 GM108569.